Search results
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 months agoAytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2024 Earnings Call Transcript February 14, 2024 Aytu...
Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Expected To Breakeven In The Near Future
Simply Wall St. via Yahoo Finance· 1 year agoWe feel now is a pretty good time to analyse Aytu BioPharma, Inc.'s (NASDAQ:AYTU) business as it...
Aytu BioPharma Inc. (AYTU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Zacks via Yahoo Finance· 1 year agoAytu BioPharma Inc. (AYTU) appears to have found support after losing some value lately, as...
There's No Escaping Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Muted Revenues
Simply Wall St. via Yahoo Finance· 8 months agoYou may think that with a price-to-sales (or "P/S") ratio of 0.1x Aytu BioPharma, Inc. (NASDAQ:AYTU)...
Aytu BioPharma Second Quarter 2024 Earnings: Beats Expectations
Simply Wall St. via Yahoo Finance· 4 months agoAytu BioPharma (NASDAQ:AYTU) Second Quarter 2024 Results Key Financial Results Revenue: US$22.9m...
US$5.50: That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After Its Latest...
Simply Wall St. via Yahoo Finance· 2 years agoAytu BioPharma, Inc. (NASDAQ:AYTU) just released its quarterly report and things are looking...
Aytu BioPharma Announces Strategic Shift, Indefinite Suspension of Clinical Development Programs
Benzinga via Yahoo Finance· 2 years agoAytu BioPharma Inc (NASDAQ: AYTU) announced a shift in the company's strategy to accelerate its...
Q3 2024 Aytu Biopharma Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 3 weeks agoParticipants Josh Disbrow; Chairman and CEO; Aytu Biopharma, Inc. Mark Oki; CFO; Aytu Biopharma, Inc. Roger Weiss; Moderator; Lytham Partners IR Naz Rahman; Analyst; Maxim Group Presentation ...
AYTU Stock Earnings: Aytu Misses EPS, Revenue Estimates
InvestorPlace via Yahoo Finance· 1 year agoAytu Biopharma (NASDAQ:AYTU) just posted results for its fiscal third quarter. Aytu reported a loss per share of $1.93. This was much worse than the analyst estimate for a loss per share of ...
Aytu BioPharma Inc (AYTU) Q3 2024 Earnings Call Transcript Highlights: Strategic Gains Amidst ...
GuruFocus.com via Yahoo Finance· 3 weeks agoADHD Portfolio Revenue: Increased 49% year-over-year to $12.3 million. Adjusted EBITDA: Improved by $7 million compared to the previous year; trailing 12-month adjusted EBITDA over $15 million ...
